Practice Update | Onology

CONFERENCE COVERAGE 10

American Society of Clinical Oncology 2017 Annual Meeting 2–6 JUNE 2017 • CHICAGO, USA

At this year’s ASCO annual meeting, the PracticeUpdate Editorial team spoke to some of oncology’s most esteemed minds for their thoughts on key clinical trial data presented at the meeting, and those they considered practice changers.

Practice changers in advanced prostate cancer: STAMPEDE, LATITUDE vis-à-vis CHAARTED

Dr Farzanna Haffizulla speaks with Oliver A Sartor MD, Laborde Professor in Cancer Research in the Medicine and Urology Departments at Tulane School of Medicine in Louisiana, on the STAMPEDE, LATITUDE and CHAARTED trials and what they mean for men with prostate cancer.

with a low-dose prednisone, only 5 mg of prednisone, add it to ADT as being a new potential standard of care. Dr Haffizulla: How does this data differ from LATITUDE? Dr Sartor: Well, the LATITUDE is a little bit more restricted, so what I didn’t tell you about STAMPEDE is it also took the non- metastatic patients, and I personally feel as though the nonmetastatic patients don’t have adequate maturity to be con- clusive. Their failure-free survival is very strongly positive on the abiraterone, but their overall survival and then the hazard ratio was good at 0.75. Confidence level is still big and not a lot of maturity in that. So, STAMPEDE actually took in a lot of the nonmetastatic patients.

Dr Haffizulla: I wanted to talk about the most recent data from STAMPEDE. We’re here at ASCO 2017 and I know in STAMPEDE we’re assessing abiraterone in the context of hor- mone-sensitive prostate cancer. What does this data mean for clinical practice? Dr Sartor: I think it’s practice changing. The utilization of ADT has been ongo- ing since 1941 and it’s sort of the standard that we’ve become accustomed to. There was a clinical trial called CHAARTED that helped change that standard by adding

in chemotherapy and STAMPEDE had another arm that added in chemotherapy. But the new data is with abiraterone, and it’s being compared against conventional ADT. It’s really strikingly positive, and within the metastatic subset almost a reduction of 40%; it’s like a 39% reduction in mortality. It’s pretty reasonably well tolerated. The PFS and other components of the endpoints were all strikingly positive, and I think it’s a practice changer. I think peo- ple are going to be looking at abiraterone

PRACTICEUPDATE ONCOLOGY